Market Signal Briefing

In brief
A new pilot scheme from Visa will enable companies to send USD and recipients to receive Circle’s USDC stablecoin.
The company says the scheme can help support gig economy workers and will roll out in the second half of 2026, pending regulators’ approval.
Visa has been making numerous investments and partnerships in the stablecoin space throughout 2025.
Visa is piloting a new scheme that will allow companies to send payments directly to recipients' stablecoin wallets, while only sending conventional fiat USD.

Firms will pay out money in fiat USD, and recipients will receive the money in dollar-pegged stablecoins like Circle’s USDC, the world’s second largest stablecoin by capitalization. It doesn’t appear that companies will be able to send stablecoins directly via the scheme.

Visa did not mention if or when support for stablecoins other than USDC would be added, though it didn't say the service would be exclusive to USDC. Anyone who wants to use the service to receive payments will need both a stablecoin wallet and to pass customary AML/KYC checks, and the pilot is currently limited to platforms and businesses based in the U.S.

Visa earmarked the service as being useful for the creator and gig economy. For example, firms like TikTok or YouTube, which deliver small, irregular payments to millions of people globally, though no participants were announced.

Visa says it is in the process of onboarding partners, with wider access projected for some point in the second half of 2026, depending on local regulations.  The pilot comes as part of Visa Direct, the payment giant’s service that allows users to conduct payments using its own payment rails rather than, for example, those of two banks.

The payments giant also didn’t confirm what payment rails the service might use, but it’s been linking up with Circle on stablecoin infrastructure as of late.

In late October, Circle announced that Visa was among the firms participating in its new public testnet for Arc, its Layer-1 blockchain network, alongside companies such as BlackRock and Goldman Sachs.

Visa eyes stablecoinsVisa has made a series of increasingly bullish moves in the stablecoin space during 2025. In May, it poured an unspecified amount into London-based stablecoin infrastructure company BVNK as a “strategic investment” via its Visa Ventures arm.

Earlier this month, Visa issued a report predicting an increased role for stablecoins in the $40 trillion global credit market, saying that stablecoin-based lending could allow traditional institutions to bring parts of that market onto programmable, blockchain-based rails.

Meanwhile, like rival Mastercard, Visa has been adding support for stablecoin-based crypto credit cards—including with fintech Rain in the U.S., and Bridge, a unit of payments giant Stripe, in Latin America. 

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

The end of Trump's last US government shutdown back in 2019 saw a boom in crypto markets, but things are a bit different this time around.

Sui launching USDsui stablecoin via Bridge amid growing adoption

Partner offers

The Block may may earn a commission if you use our partner offers, at no extra cost to you.

Quick Take
USDsui is designed to serve as a foundational stablecoin for the Sui network.
The token will be interoperable with stablecoins on Phantom, Hyperliquid, and MetaMask.
Sui is planning to launch its own stablecoin via Bridge's Open Issuance as the U.S. dollar-pegged tokens edge further into the financial mainstream.

"USDsui is designed to serve as a foundational stablecoin for the Sui network," according to a statement. "It offers builders a fully integrated, compliant-ready solution that is interoperable across Bridge’s ecosystem and optimized for Sui’s high-performance architecture."

As stablecoin supply maintains steady growth, traditional financial firms like Standard Chartered and Visa are taking a direct interest in stablecoins.

The new stablecoin, to be launched this year, will be accessible across wallets, DeFi protocols, and applications built on Sui's Layer 1 blockchain. The token will be interoperable with stablecoins on Phantom, Hyperliquid, and MetaMask, Sui said in Wednesday's statement.

"USDsui adds another crucial piece of infrastructure that fully leverages the performance and scalability of the Sui Network, augments its existing native stablecoin offerings and gives developers and users a trusted digital dollar that leverages Sui’s unparalleled performance," according to Adeniyi Abiodun, co-founder at Mysten Labs, Sui's core developer.

The stablecoin is meant to comply with the GENIUS Act, the U.S. government's framework for stablecoins, passed into law earlier this year.

Disclaimer: The Block is an independent media outlet that delivers news, research, and data. As of November 2023, Foresight Ventures is a majority investor of The Block. Foresight Ventures invests in other companies in the crypto space. Crypto exchange Bitget is an anchor LP for Foresight Ventures. The Block continues to operate independently to deliver objective, impactful, and timely information about the crypto industry. Here are our current financial disclosures.

© 2025 The Block. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

AUTHOR RT Watson is a senior reporter at The Block who covers a wide array of topics including U.S.-based companies, blockchain gaming and NFTs. Formerly covered entertainment at The Wall Street Journal, where he wrote about Disney, Netflix, Warner Bros. and the creator economy while focusing primarily on technological disruption across media. Previous to that he covered corporate, economic and political news in Brazil while at Bloomberg. RT has interviewed a diverse cast of characters including CEOs, media moguls, top influencers, politicians, blue-collar workers, drug traffickers and convicted criminals. Holds a master's degree in Digital Sociology. See More

WHO WE ARE The Block is a news provider that strives to be the first and final word on digital assets news, research, and data. +
Follow us on Google News
More by RT Watson

TL;DR:

MET token rises nearly 30%, reclaiming $0.51 as post-airdrop slump fades.
Meteora generates $1.12B in annualized fees, approaching Uniswap’s multi-chain performance.
Weekly volumes exceed $5B; liquidity and new exchange listings may fuel further growth, though a short-term correction is possible due to concentrated whale activity.

Meteora’s MET token is regaining momentum after its initial post-airdrop slump, with traders eyeing its DEX activity and fee generation. MET expanded nearly 30%, reclaiming a price above $0.51, though it has yet to return to its initial post-airdrop high of $0.61. The token’s recovery reflects renewed buying interest, especially as trading volumes on Bybit surged in recent weeks.

ADA-Like Performance as Meteora Races Toward Top DEX Status
Open interest is building, with $62M in positions, primarily on the Bybit derivatives market. A top whale has realized $1.4M in profits, while other influential holders mostly exited with smaller gains. Active decentralized pairs, including one with $4.5M in liquidity, support the rally. The token’s trajectory depends on liquidity inflows and additional exchange listings, which Meteora encourages to strengthen pool depth.

Meteora ranks among Solana’s top 10 fee producers, generating $1.12B in annualized fees and $102M in October alone. It is closing in on Uniswap, which commands $1.31B in annualized fees and $132M for October. Unlike Uniswap’s multi-chain reach, Meteora’s success stems solely from Solana, making its performance particularly notable.

The DEX facilitates trades between stablecoins and popular meme tokens, occasionally spiking during brief activity surges for assets like TRUMP and MELANIA. Weekly volumes surpass $5B, positioning Meteora just behind Raydium, Solana’s leading DEX. The platform also expects token burns and buybacks, similar to recent UNI activity, which could push MET into a higher price range.

Renewed trader optimism is evident, with only four whales actively using Hyperliquid and one holding a significant long. Additional centralized exchange listings, coupled with liquidity growth, could further accelerate MET’s price discovery. Analysts note that while the current 30% rally is impressive, a short-term correction is possible given the rapid gains and concentration of whale activity.

CRWD's shares jump 29.1% in three months as strong demand for its Falcon Flex and Next-Gen SIEM fuels growth momentum.

LAS VEGAS, Nov. 12, 2025 (GLOBE NEWSWIRE) -- via IBN -- Suntex Enterprises Inc. is pleased to announce that it has achieved OTCID Verified status on OTC Markets and has officially appointed Javier Leal as its new Chief Executive Officer. These actions mark the beginning of a comprehensive corporate restructuring and expansion initiative designed to position Suntex for accelerated growth and long-term shareholder value creation.

NASDAQ 100 Technical Analysis
The Nasdaq 100 moved slightly higher in pre-market trading on Wednesday, consolidating as it decides whether to continue its uptrend. It appears likely to do so, as optimism grows around the potential end of the government shutdown development which has boosted sentiment. Realistically, this serves as an excuse for traders to resume buying, but the trend remains intact. The index has been in a steady upward channel, briefly breaking above it before pulling back to retest it as support. This behavior reinforces the strength of the broader uptrend. The 25,000 level should now act as a strong floor for the Nasdaq 100.

Dow Jones 30 Technical Analysis
The Dow Jones 30 also looks ready to push higher in pre-market trading, now positioned above the crucial 48,000 level. The market continues to favor a “buy on the dip” approach, with near-term support expected around 47,000 and the 50-day EMA just below that. A move toward the 49,000 level is possible, driven by psychological momentum.

– Multiple presentations on vimseltinib for the treatment of Tenosynovial Giant Cell Tumor (TGCT), including encore data from the Phase 3 MOTION study presented in an oral session –

– Two posters on DCC-3009 in Gastrointestinal Stromal Tumor (GIST) –

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that data from multiple pipeline programs, including long-term and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option, will be presented during the CTOS Annual Meeting 2025, taking place November 12-15 in Boca Raton, Florida.

“We are excited about the breadth of data we’re presenting at CTOS this year, which underscore the strong progress we continue to sustain across our pipeline,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “We look forward to sharing encore data from our Phase 3 MOTION study of vimseltinib and providing updates on our DCC-3009 Phase 1 program, which demonstrate how we can expand our GIST treatment capabilities by targeting known primary and secondary drug-resistant mutations spanning multiple KIT exons.”

Oral and Poster presentation details are as follows:

Title: Long-Term Efficacy and Safety of Vimseltinib in Patients (Pts) with Tenosynovial Giant Cell Tumor (TGCT): Results from the MOTION Phase 3 Trial

Presenter: Silvia Stacchiotti, M.D., Fondazione IRCCS Istituto Nazionale Dei Tumori

Session Title: Session 8: TGCT & Desmoid Tumor

Session Date: Friday, November 14, 2025

Session Time: 2:30 – 3:30 PM ET

Title: Impact of Expert-Led Education Programs on Health Care Provider (HCP) Knowledge of Gastrointestinal Stromal Tumor (GIST)

Presenter: Mark Agulnik, M.D., USC Norris Comprehensive Cancer Center, University of Southern California

Poster Reception: Thursday, November 13, 2025

Session Time: 5:30 – 6:30 PM ET

Title: Efficacy with Vimseltinib in Patients (Pts) with Tenosynovial Giant Cell Tumor (TGCT) and Prior Colony-Stimulating Factor 1 (CSF1) Inhibitor Therapy: A Phase 2 Case Series

Presenter: Andrew J. Wagner, M.D., Ph.D., Harvard Medical School, Dana-Farber Cancer Institute

Poster Reception: Thursday, November 13, 2025

Session Time: 5:30 – 6:30 PM ET

Title: Effect of a High-Fat Meal on the Pharmacokinetics (PK) of Vimseltinib, an Oral Inhibitor of the Colony-Stimulating Factor 1 Receptor (CSF1), in Healthy Participants

Presenter: Chengyue Zhang, Ph.D., Deciphera Pharmaceuticals, LLC

Poster Reception: Thursday, November 13, 2025

Session Time: 5:30 – 6:30 PM ET

Title: Effect of Itraconazole (ITX) and Rabeprazole (RBP) on the Pharmacokinetics (PK) of Vimseltinib, an Oral Inhibitor of the Colony-Stimulating Factor 1 Receptor (CSF1), in Healthy Participants

Presenter: Chengyue Zhang, Ph.D., Deciphera Pharmaceuticals, LLC

Poster Reception: Thursday, November 13, 2025

Session Time: 5:30 – 6:30 PM ET

Title: An Open-Label Phase 1/2 Study of DCC-3009 Monotherapy in Patients (Pts) with Advanced Gastrointestinal Stromal Tumor (GIST)

Presenter: Suzanne George, M.D., Division of Sarcoma, Dana-Farber Cancer Institute - Sarcoma Center

Poster Reception: Thursday, November 13, 2025

Session Time: 5:30 – 6:30 PM ET

About Deciphera Pharmaceuticals Inc.

Deciphera, a member of Ono Pharmaceutical Co., Ltd., is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines and providing hope to people living with cancer, neurologic and autoimmune disease. Deciphera is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from Deciphera’s platform in clinical studies, QINLOCK® (ripretinib) is Deciphera’s switch-control kinase inhibitor approved in many countries including the European Union and the United States for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. ROMVIMZA™ (vimseltinib) is a kinase inhibitor approved in the United States for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity, and in the European Union for adult patients with TGCT associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).

About Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of “Dedicated to the Fight against Disease and Pain,” Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at https://www.ono-pharma.com/en .

Cautionary Note Regarding Forward-Looking Statements

In this press release, statements made with respect to current plans, estimates, strategies and beliefs, and other statements that are not historical facts are forward-looking statements about the future performance of the company. These statements are based on current assumptions and beliefs in light of the information currently available and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in the business environment in the pharmaceutical market and amendments to relevant laws and regulations, (ii) disruptions to product supply due to stagnation or delays in production caused by natural disasters, fires, etc., (iii) the possibility that sales activities for new and existing products may not achieve the expected results, (iv) the emergence of new side effects in post-marketing drugs, and (v) infringements of intellectual property rights by third parties. Information about pharmaceutical products included in this press release is not intended to constitute an advertisement or medical advice.

More News From Deciphera Pharmaceuticals Inc.

LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Savers Value Village, Inc. (“Savers” or “the Company”) (NYSE: SVV) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Savers reported its Q3 financial results on October 30, 2025. The Company reported a GAAP loss of $0.09 per share. Based on this news, shares of Savers fell by more than 30% on the next day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm 
Brian Schall, Esq. 
310-301-3335
[email protected]

www.schallfirm.com

Platform release unifies data security, cyber recovery, and identity resilience across cloud, hybrid, and on-premises environments to enable continuous business at enterprise scale

, /PRNewswire/ -- SHIFT 2025 – Commvault (NASDAQ: CVLT), a leader in unified resilience at enterprise scale, today announced the Commvault Cloud Unity platform release, one of the most substantive platform releases in Commvault's history. This next-generation, AI-enabled version of Commvault Cloud now unifies data security, cyber recovery, and identity resilience across cloud, SaaS, on-premises, and hybrid environments.

Today security and IT teams are grappling with three distinct challenges:

AI is creating exponential volumes of distributed data, which introduces more threat vectors for bad actors to exploit.
Enterprises are using siloed products to secure, protect, manage, and recover data – tools that were never designed to work together.
There is no one-size-fits-all approach – enterprises are spread across on-premises, cloud, and hybrid environments and need resilience for all.

Commvault addresses these challenges with the Commvault Cloud Unity platform release.

"Enterprises are facing the perfect storm: non-stop cyber threats, exacerbated by AI; attacks on identity systems; and recovery challenges that impact revenues and reputations," said Pranay Ahlawat, Chief Technology and AI Officer, Commvault. "Commvault brought together the best engineering minds to create a transformative platform release that not only unifies resilience across disciplines and environments but can also help customers drive strong business outcomes."

Bringing Together Data Security, Cyber Recovery, and Identity Resilience

By unifying these disciplines on one platform, customers have access to an industry-leading set of solutions that work seamlessly across their deployment options of choice.

Data Security: Commvault's data security capabilities embedded within the platform include AI-enabled discovery, classification, and protection policy recommendations along with data and AI access governance and active monitoring and enforcement. Commvault Cloud's powerful set of data security capabilities will be enhanced by the recent acquisition of Satori Cyber.
Cyber Recovery: Customers have access to transformative AI-enabled recovery capabilities that can foster the fastest, most complete recoveries. For example, following a cyberattack, IT and security teams can rely on Commvault's new Synthetic Recovery offering to surgically remove compromised data while recovering the rest.
Identity Resilience: Commvault is expanding its end-to-end Identity Resilience portfolio offerings that help enterprises detect, audit, and reverse hard-to-detect threats in identity systems like Active Directory. For more on Commvault's latest identity resilience innovations, click here.

"There have been hints of this type of platform in the industry where these disciplines are coming together," said Jo Peterson, VP Cloud and Security, Cleartech Research. "But for the first time, Commvault has done it in a meaningful way that will truly advance resilience for enterprises globally."

Extended Benefits of the Commvault Cloud Unity Platform Release

Unified protection across all workloads, clouds and locations: By centralizing protection and recoverability, organizations can decrease downtime and increase availability of trusted data that businesses require to run in the AI era. For more on how Commvault is bringing new levels of resilience to cloud-first enterprises, click here.
Unified governance across separate operations: Traditionally, security, identity, and recovery teams apply separate tools to disconnected operations. With the Unity platform release, Commvault is changing that, unifying access and data policy monitoring, enforcement, and threat detection to drive rapid action and clean recovery.
Unified intelligence across disparate systems: There is tremendous power in combining data security intelligence, identity and access patterns, and clean recovery analysis on a single platform. The result is AI-enabled action that is designed to help customers optimize resilience.

"Data security is the foundation of mission-critical IT infrastructure systems," said Allen Downs, Security & Resiliency Vice President, Kyndryl. "By strengthening cyber resilience and recovery for essential services, organizations can better prepare to anticipate, protect against, withstand and recover from potentially disruptive events. In today's environment, resiliency is an imperative."

Availability
Parts of the Commvault Cloud Unity platform release will be available starting later this year, with feature rollouts continuing into early 2026.

Learn More at SHIFT 2025
This announcement complements other significant announcements at SHIFT 2025, including distinctive innovations that are changing the game in cloud native data protection, identity resilience, and cyber recovery.

To get a first-hand look at all of these announcements, please join Commvault at SHIFT 2025 virtually on November 19 (register here). 

About Commvault

Commvault (NASDAQ: CVLT) is a leader in unified resilience at enterprise scale. In a constantly evolving threat landscape, Commvault keeps customers ready by unifying data security, identity resilience, and cyber recovery, on one cloud-native, AI-enabled platform. Customers trust Commvault to conduct the fastest, most complete recoveries – not just their data, but their entire business. Purpose-built for the agentic enterprise, Commvault also enables organizations to safely embrace AI while protecting against AI-driven threats. 

SOURCE COMMVAULT

Delivers a modern, AI-enabled interface that centralizes resilience operations across clouds, regions and on-premises environments, including data centers and edge locations

, /PRNewswire/ -- SHIFT 2025 – Commvault (NASDAQ: CVLT), a leader in enterprise resilience for the AI era, today announced that via the Commvault Cloud Unity platform release, the company is setting a new benchmark for cloud-native data protection.

Purpose-built for cloud-first and hybrid enterprises, the new release introduces a re-engineered experience designed for simplicity, speed, scale, and cost optimization, as Commvault centralizes resilience operations across clouds, regions, and accounts. With AI-enabled discovery, classification, and protection policy recommendations, this platform is designed to scale resilience in minutes across multi-cloud environments – at the best TCO.

As cloud adoption accelerates, decentralization has amplified the challenges of fragmented tools, inconsistent protection policies, and limited visibility. With 86% of enterprises now operating in multi-cloud environments1 and nearly half of all cloud spend wasted due to lack of visibility,2 the need for a unified approach has never been greater. 

Unlike tools that only protect within their own ecosystem, Commvault's latest platform release gives cloud teams a clear view of what's protected, and what isn't – highlighting the risk of unprotected data. It also provides visibility into the cost advantages of Commvault Cloud compared to other cloud solutions and providers, to create, store, manage, and recover secure copies of sensitive data.

In addition, the new platform interface enables easy docking of on-premises workloads from data centers and edge locations to further centralize governance across all data, no matter where it lives. With coverage spanning 160+ cloud regions and protection for over 200 cloud services, Commvault delivers the industry's broadest workload protection and global resilience.

"Simplified onboarding for every workload — powered by AI-enabled discovery and recommendations within a unified cloud experience is a true game changer," said Hamzah Mahafzah, Enterprise Architecture Director, Najm. "We will instantly see anomalies, identify unprotected data, and make smarter, faster decisions – all while driving lower TCO."

Now also available in both Microsoft Azure and AWS marketplaces, the platform release empowers organizations to:

Rapidly Onboard with AI-Enabled Simplicity: An AI-enabled experience automatically finds workloads across an organization's cloud estates and recommends protection policies based on workload classification while supporting compliance initiatives.
Analyze Cloud Data Risk: Discovered cloud resources are analyzed for protection risk, with reports that include status of existing snapshots of discovered workloads, so cloud administrators can see protected versus under-protected workloads.
Customer-Specific TCO Analysis: After automatically discovering cloud resources, customers benefit from a TCO analysis that displays a list of unprotected and cloud-protected workloads (e.g., cloud snapshots), and the expected TCO savings the user would see by protecting those workloads with Commvault Cloud.
Unparalleled Multi-Cloud and Hybrid Support: This platform release is designed to unify protection across clouds, regions, and accounts and extends to protect on-premises environments across data centers and edge locations – all in one centralized UI.
Integrated Cyber Resilience: For customers that want to go beyond the simple native cloud backup solutions offered by hyperscalers, Commvault Cloud makes it easy to add additional, integrated cyber resilience capabilities.

"Enterprises today are evolving from managing data in silos to orchestrating it across diverse cloud environments," said Shelly Kramer, Principal Analyst, Kramer and Co. "The Commvault Cloud Unity platform release advances this shift by streamlining management, helping enterprises close protection gaps, optimizing costs, and transforming cloud native protection from an operational burden to a strategic advantage."

"We want to meet cloud-first and hybrid customers where they are today and will be tomorrow," said Rajiv Kottomtharayil, Chief Product Officer, Commvault. "That means giving enterprises the speed, precision, visibility, and confidence to protect, recover, and rebuild their data and applications anywhere in the cloud all via one simple, intelligent experience."

Availability and Global Access
The capabilities included in this press release are generally available today as are the consumption-based pricing models, via the AWS and Microsoft Azure marketplaces. To learn more about these capabilities, visit our blog here.

Learn More at SHIFT 2025
This announcement complements other significant announcements at SHIFT 2025, including the company's Commvault Cloud Unity platform release and other distinctive innovations that are changing the game in identity resilience and cyber recovery.

To get a first-hand look at all of these announcements, please join Commvault at SHIFT 2025 virtually on November 19 (register here). 

About Commvault
Commvault (NASDAQ: CVLT) is a leader in unified resilience at enterprise scale. In a constantly evolving threat landscape, Commvault keeps customers ready by unifying data security, identity resilience, and cyber recovery, on one cloud-native, AI-enabled platform. Customers trust Commvault to conduct the fastest, most complete recoveries – not just their data, but their entire business. Purpose-built for the agentic enterprise, Commvault also enables organizations to safely embrace AI while protecting against AI-driven threats.

1 Microsoft. (2024). State of Multi-Cloud Risk Report. https://cdn-dynmedia-1.microsoft.com/is/content/microsoftcorp/microsoft/final/en-us/microsoft-brand/documents/2024-State-of-Multicloud-Security-Risk-Report.pdf

2 Stormforge. (2022) StormForge Kubernetes & Cloud Waste Survey.
https://stormforge.io/survey-report/stormforge-2022-kubernetes-cloud-waste-survey/ 

SOURCE COMMVAULT

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CRWV over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

CHENGDU, CN / ACCESS Newswire / November 12, 2025 / WeTouch Technology Inc. (NASDAQ:WETH) ("WeTouch" or the "Company"), a global leader in touch display solutions, today announced its unaudited financial results for the third quarter and nine months ended September 30, 2025.

Nine-Month (First Three Quarters) Fiscal Year 2025 Highlights

Total Revenue: $39.9 million, up 3.4% from $38.6 million in the same period of 2024.

Gross Profit: $13.7 million, up 8.7% from $12.6 million in the same period of 2024.

Net Income: $7.3 million, an increase of 23.7% year-over-year compared with $5.9 million.

Operating Cash Flow: Positive $8.5 million, compared with negative $0.7 million in the same period last year.

Cash Reserves: $113.2 million as of September 30, 2025, equivalent to approximately $9.48 per share, compared with $106.7 million a year earlier.

Shareholders' Equity: $135.2 million as of September 30, 2025, representing a 4.8% increase from $129.5 million a year ago.

Management Commentary

"WeTouch continued to deliver resilient results and solid profitability through the first three quarters of fiscal 2025," said Zongyi Lian, Chief Executive Officer of WeTouch Technology Inc. "Although third-quarter gross margin was affected by raw material cost inflation, overall profitability and cash generation remained strong. Year-to-date net income increased nearly 24% year-over-year, supported by disciplined operations and growing domestic demand in China."

Mr. Lian continued, "Our Chengdu facility construction is progressing smoothly and remains on schedule for completion by the end of 2025, with mass production expected in the second quarter of 2026. Backed by over $113 million in cash and a debt-free balance sheet, WeTouch is well-positioned to execute its next phase of capacity expansion and technology upgrades. Given its strong cash position and sustainable profitability, the Company continues exploring various strategies to increase long-term shareholder value."

Business Highlights and Outlook

China Market: Revenue rose 9.7% year-over-year in the first three quarters, led by growth in automotive and industrial touchscreen segments.

Overseas Market: Revenue decreased 7.9% year-over-year due to weaker demand in medical and gaming sectors, though customer diversification improved in Europe and Korea.

Strategic Direction: The Company continues to invest in curved and large-format technologies and to enhance efficiency through automation and local supply chain optimization.

2025 Outlook: Management expects continued profitability, strong cash flow, and steady progress in capacity expansion, supported by solid financial fundamentals and a growing domestic market presence.

About WeTouch Technology Inc.

Wetouch Technology Inc. is at the forefront of providing premium touch display solutions, dedicated to reshaping human-machine interaction across diverse industries. With a relentless focus on innovation and customer satisfaction, Wetouch consistently delivers cutting-edge technology and unparalleled performance in touch display solutions globally.

For additional information, please visit: WeTouch Technology Inc.at http://en.usa-wetouch.com/

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "anticipates", "future", "intends", "plans", "believes", "estimates", "target", "going forward", "outlook," "objective" and similar terms. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond Datasea's control, which may cause Datasea's actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to Datasea as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in Datasea's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Datasea does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Investor and Media Contact:
Email: [email protected]

SOURCE: Wetouch Technology Inc.

EnWave Corp (TSX-V:ENW, OTC:NWVCF) announced that it has signed a royalty-bearing, commercial license agreement with Shinyway International Limited, a service provider of cannabis processing based in New Zealand. 

Under the terms of the deal, Shinyway has been licensed to use EnWave’s patented Radiant Energy Vacuum (REV) technology to produce cannabis products in New Zealand. 

The vacuum microwave dehydration provider said Shinyway will pay a royalty commensurate with certain other existing licenses granted by EnWave. 

The company noted that it intends to continue working closely with Shinyway to ensure optimal product development success.  

Shinyway, which provides drying and trimming services for cannabis growers, plans to initially install one 10-kilowatt REV machine to maximize its competitive edge in drying service by using EnWave’s technology.   

Opus Genetics, Inc. (IRD - Free Report) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +14.29%. A quarter ago, it was expected that this company would post a loss of $0.25 per share when it actually produced a loss of $0.12, delivering a surprise of +52%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Opus Genetics, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $3.08 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 11.36%. This compares to year-ago revenues of $3.87 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Opus Genetics, Inc. shares have added about 65.6% since the beginning of the year versus the S&P 500's gain of 16.4%.

What's Next for Opus Genetics, Inc.?While Opus Genetics, Inc. has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Opus Genetics, Inc. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.12 on $3.75 million in revenues for the coming quarter and -$0.56 on $13.67 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Immatics (IMTX - Free Report) , has yet to report results for the quarter ended September 2025.

This company is expected to post quarterly loss of $0.50 per share in its upcoming report, which represents a year-over-year change of -316.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Immatics' revenues are expected to be $12.3 million, down 77.9% from the year-ago quarter.

Key Takeaways CELH shares fell about 27% after Q3 despite net sales rising 173% to $725.1 million.
Management warned Q4 will be "noisy" as Alani Nu moves to PepsiCo's DSD and Rockstar integration continues.
CELH's partnership with PepsiCo continues to drive retail reach and strengthen its U.S. energy drink share.

Celsius Holdings, Inc. ((CELH - Free Report) ) shares have fallen about 27% since the company reported its third-quarter fiscal 2025 results on Nov. 6. Despite solid quarterly results, investors reacted cautiously amid near-term business transitions, integration costs and concerns about the stock’s rich valuation.

Due to this pullback, CELH has underperformed the industry, broader Zacks Consumer Staples sector, as well as the S&P 500 in the past month. In the said time frame, Celsius Holdings’ shares have tumbled 28.4% compared with the industry and sector’s respective declines of 5.3% and 0.6%. Meanwhile, the S&P 500 grew 3.2%.

Image Source: Zacks Investment Research

CELH’s Solid Underlying Q3 PerformanceCelsius Holdings delivered another quarter of impressive growth in the third quarter of 2025. Net sales surged 173% year over year to $725.1 million, supported by strong performance from the CELSIUS brand and added contributions from Alani Nu and Rockstar, which were acquired earlier in the year. The combined portfolio now holds roughly 21% of the U.S. energy drink market, highlighting CELH’s growing scale and brand relevance.

Profitability also remained strong. The company delivered adjusted earnings per share of 42 cents, up from 30 cents reported in the year-ago period, while adjusted EBITDA climbed to $205.6 million, reflecting ongoing margin expansion and operational efficiency. These results show that Celsius Holdings continues to execute well despite absorbing multiple acquisitions and distribution changes during the quarter.

Short-Term Hurdles Raise Concerns for CELHEven with strong adjusted results, management warned that the fourth quarter will be “noisy.” The company is in the middle of transitioning parts of the Alani Nu business into PepsiCo’s ((PEP - Free Report) ) direct-store-delivery (DSD) system while integrating Rockstar into its operations. These transitions are expected to cause temporary fluctuations in sales and margins as inventory levels normalize and logistics are restructured.

Celsius Holdings also noted potential headwinds from freight, scrap and tariff-related costs, along with short-term promotional timing shifts that could affect quarterly comparisons. While none of these issues appear structural, they create uncertainty around near-term performance and may take a few quarters to smooth out.

Is Celsius Holdings’ Growth Engine Intact?Despite the short-term turbulence, Celsius Holdings’ underlying momentum remains strong. Retail takeaway data showed CELSIUS brand sales increased 13% year over year, while Alani Nu maintained its strong growth trajectory, supported by new flavor launches and limited-time offerings. The company’s strategic partnership with PepsiCo continues to be a major growth driver, expanding Celsius’ reach across key channels and increasing shelf presence nationwide.

Celsius also strengthened its balance sheet after the quarter ended, reducing debt by $200 million to lower interest expenses and improve financial flexibility heading into 2026. Management highlighted that PepsiCo’s continued support reinforces confidence in Celsius Holdings’ long-term potential and positions the combined portfolio for sustained market share gains.

Which Way Are CELH Estimates Headed Post Results?Analysts’ earnings estimates for Celsius Holdings have moved higher following the results, suggesting that they see the current challenges as temporary and expect the company to sustain strong growth into 2026. The Zacks Consensus Estimate for 2025 and 2026 EPS has moved higher in the past seven days.

Image Source: Zacks Investment Research

CELH Stock Still Appears PriceyWhile Celsius Holdings’ fundamentals remain solid, valuation continues to be a concern. The stock’s forward 12-month P/E of 29.67X stands well above the industry average of 14.48X. Its Value Score of D further suggests limited room for multiple expansion in the near term. In comparison, other beverage leaders such as PepsiCo, Keurig Dr Pepper ((KDP - Free Report) ) and Coca-Cola ((KO - Free Report) ) all trade at more moderate valuations of 17.07X, 12.42X and 22.46X, respectively.

Image Source: Zacks Investment Research

CELH’s premium reflects its faster growth trajectory, but it also means the stock could remain volatile if margins or volumes underperform expectations.

CELH: In a NutshellCelsius Holdings delivered another quarter of strong growth, expanding its top line and adjusted profitability while continuing to integrate its recent acquisitions. The stock’s sharp post-earnings decline seems driven more by short-term transition noise than by weakness in the underlying business. With earnings estimates trending upward and demand for energy drinks holding steady, CELH remains a compelling growth story in the beverage space. However, given the ongoing integration work and elevated valuation, investors may prefer to wait for clearer signs of margin stability before considering new positions.

Celsius Holdings currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Rockwell Medical, Inc. (RMTI) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST

Company Participants

Heather Hunter - Senior VP & COO
Mark Strobeck - President, CEO & Director
Jesse Neri - Senior VP & CFO

Conference Call Participants

Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division
Nicholas Sherwood - Maxim Group LLC, Research Division
Anthony Vendetti - Maxim Group LLC, Research Division

Presentation

Operator

Good morning, and welcome to Rockwell Medical's Third Quarter 2025 Results Conference Call and Webcast. Please note, this event is being recorded. At this time, I would like to turn the conference call over to Heather Hunter, Chief Operating Officer at Rockwell Medical. Heather, please go ahead.

Heather Hunter
Senior VP & COO

Good morning, and thank you for joining us for this update on Rockwell Medical. Joining me on today's conference call are Dr. Mark Strobeck, Rockwell Medical's President and Chief Executive Officer; and Jesse Neri, Rockwell Medical's Chief Financial Officer.

Before we begin, I would like to remind you that this conference call will contain forward-looking statements about Rockwell Medical within the meaning of the federal securities laws, including, but not limited to, the types of statements identified as forward-looking in our annual report on Form 10-K and our subsequent periodic reports filed with the SEC. These statements are subject to risks and uncertainties that could cause actual results to differ.

Please note that these forward-looking statements reflect our opinions and expectations only as of today. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our periodic reports filed with the SEC.

Recommended For You

TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO® system with Getz Healthcare, a leading distributor of medical devices, equipment and consumables, in Australia and New Zealand.

The TULSA Procedure™, performed using Profound’s TULSA-PRO system, is a significant advancement in prostate care. Instead of surgery or radiation, treatment is performed inside an MRI suite using robotically controlled, directional ultrasound to precisely ablate prostate tissue while protecting surrounding structures. TULSA-PRO is the only AI-powered, MR-guided robotic system for prostate therapy, enabling real-time MRI thermography and autonomous temperature control. This allows physicians to see, monitor and adjust treatment throughout the procedure — delivering personalized therapy with exceptional precision.

"Our exclusive partnership with Profound Medical marks a significant step in advancing precision prostate care across Australia and New Zealand,” commented Getz Healthcare ANZ Managing Director, Derek Foltin. “The TULSA-PRO system strengthens our commitment to deliver innovative, clinically proven technologies that improve patient outcomes and further advances our position in prostate cancer surgery and minimally invasive therapies.”

“Like in many other regions around the globe, prostate cancer is the most commonly diagnosed cancer in men in Australasia,” said Arun Menawat, Profound’s CEO and Chairman. “We are excited to gain access to this significant market for TULSA-PRO. Beyond Australia and New Zealand, we are actively pursuing other potential opportunities to expand our strategic commercial partnership with Getz Healthcare to include additional key markets across Asia Pacific.”

As user interest in Profound’s technologies continues to build, the Company is deploying its own direct sales team in North America, while partnering with select strategic distribution partners to support the business potential and the customer base in other parts of the world.

About Getz Healthcare

Getz Healthcare is proud to be recognised as the leading distributor of medical equipment, devices and consumables in Asia Pacific. We are an ISO 9001:2015 certified company, and we partner with leading manufacturers in medical technology, to offer a wide range of innovative and high-quality products & solutions, enabling our customers to focus on what’s important – providing better care for their patients.

Headquartered in Singapore, we have been operating in the Asia region for over 110 years, serving over 7,500 customers from our 23 offices and distribution centres spread across Australia, Hong Kong, Malaysia, New Zealand, Pakistan, Philippines, Taiwan, Thailand and Vietnam.

Getz Healthcare is part of The Getz Group of companies. The company’s mission is to bring meaningful healthcare solutions to the people of Asia Pacific.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. The TULSA Procedure is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with the TULSA Procedure. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

Forward-Looking Statements

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment and osteoid osteoma; the extent and timing of Profound’s completion of TULSA-PRO® system sales from its qualified sales pipeline; Profound’s expectations for future revenues; and the success of Profound’s commercialization strategy and activities for TULSA-PRO. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound's Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.ca and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

For further information, please contact:

For Profound Medical

Stephen Kilmer
Investor Relations
[email protected]
T: 647.872.4849

Susan Thomas
Public Relations
[email protected]
T: 619.540.9195

For Getz Healthcare

Ben Stungo
Business Development Manager - Advanced Technologies
[email protected]
T: +61 437 010 133

November 12, 2025 08:30 ET

 | Source:

IO Biotech

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that members of its senior management team will participate in the following upcoming investor conferences:

Event: Jefferies Global Healthcare Conference
Location: London
Presentation: Tuesday, November 18, 2025, at 3:00 PM GMT
Presenter: Mai-Britt Zocca, PhD, President & CEO
Webcast Link: https://wsw.com/webcast/jeff332/iobt/1846538

Event: Piper Sandler 36th Annual Healthcare Conference
Location: New York
Fireside chat: Wednesday, December 3, 2025, at 3:00 pm ET
Presenter: Mai-Britt Zocca, PhD, President & CEO
Webcast Link: https://event.webcasts.com/starthere.jsp?ei=1742757&tp_key=8b79a34402

A webcast replay of the Jefferies corporate presentation and Piper fireside chat will be available on IO Biotech’s website at www.iobiotech.com for 90 days following the presentation.

About IO Biotech

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio®, in clinical trials, and additional pipeline candidates through preclinical development. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.

For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including statements regarding the timing or outcome of communications with regulatory authorities including the FDA, the timing or outcome of the submission of regulatory applications, including an IND for IO112, and statements regarding other current or future clinical trials, their timing, progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

Contact:

Investors and media:
Maryann Cimino, Director of Investor Relations & Corporate Communications
IO Biotech, Inc.
617-710-7305
[email protected]

The stock-based purchase strengthens Amaze’s position in the growing food and beverage creator economy

November 12, 2025 08:30 ET

 | Source:

Amaze Holdings, Inc

NEWPORT BEACH, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze”) a global leader in creator-powered commerce, today announced it has completed the acquisition of the assets of The Food Channel®, a prominent digital platform dedicated to culinary content and inspiration. The purchase price for the assets was $650,000 payable in the form of a convertible promissory note issued by Amaze. The purchase marks a key step in Amaze’s strategy to expand into new creator verticals.

The acquisition enables Amaze to combine its network of food creators with The Food Channel’s established digital brand to power a next-generation social commerce and entertainment platform. The Amaze team is currently developing an all-new FoodChannel.com, designed to deliver an immersive, community-driven experience. This will allow Amaze’s 60,000 plus food creators to engage new audiences and brands at the redesigned FoodChannel.com.   

“Food and dining creators are among the most passionate and engaged communities online,” said Aaron Day, CEO of Amaze. “Bringing creators and fans together under The Food Channel brand allows us to deliver a more meaningful and interactive experience. With the purchase officially complete, we are focused on building an enhanced integrated e-commerce solution that celebrates creativity, drives community, and turns passion for food into opportunity.”

Danielle Pederson, CMO of Amaze, added: “Since announcing our intent to purchase The Food Channel in September, we’ve seen an incredible response from brands, product companies, media companies and food creators alike. The Food Channel name carries strong credibility, and the excitement to collaborate and innovate around this next chapter has been tremendous.”

Founded as a print publication in 1989, The Food Channel transitioned online in 1993 and later joined the USA Today network in 2017 to expand its reach. With over three decades of culinary leadership, The Food Channel has continuously adapted to new mediums and platforms, making it easy for food enthusiasts to indulge in their passion and explore the many ways food intersects with life. Amaze’s ownership will build upon that legacy, providing creators with the AI-backed technology and suite of tools needed to achieve sustainable success.

For investor information, please contact

[email protected] press inquiries, please contact

[email protected] Amaze:
Amaze Holdings, Inc. is an end-to-end, creator-powered commerce platform offering tools for seamless product creation, advanced e-commerce solutions, and scalable managed services. By empowering anyone to “sell anything, anywhere,” Amaze enables creators to tell their stories, cultivate deeper audience connections, and generate sustainable income through shoppable, authentic experiences. Discover more at

www.amaze.co.

About The Food Channel:
The Food Channel has been a trusted source for food & beverage enthusiasts since 1989. The company built a loyal following by offering consumers informative recipes, articles and videos about food and culture, and providing a platform where content-makers can share their food-related content. The company is transforming into a platform to enable food & beverage creators and influencers to monetize their audiences, and adding e-commerce, online culinary classes, virtual cooking events, and culinary travel experiences.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements relate to future events and developments or to our future operating or financial performance, are subject to risks and uncertainties and are based on estimates and assumptions. Forward-looking statements may include, but are not limited to, statements about our planned acquisitions, strategies, initiatives, growth, revenues, expenditures, the size of our market, our plans and objectives for future operations, and future financial and business performance. These statements can be identified by words such as such as “may,” “might,” “should,” “would,” “could,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue,” and are based our current expectations and views concerning future events and developments and their potential effects on us.

These statements are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to differ materially from those projected or otherwise implied by the forward-looking statement. These risks include: our ability to execute our plans and strategies; our limited operating history and history of losses; our financial position and need for additional capital; our ability to attract and retain our creator base and expand the range of products available for sale; we may experience difficulties in managing our growth and expenses; we may not keep pace with technological advances; there may be undetected errors or defects in our software or issues related to data computing, processing or storage; our reliance on third parties to provide key services for our business, including cloud hosting, marketing platforms, payment providers and network providers; failure to maintain or enhance our brand; our ability to protect our intellectual property; significant interruptions, delays or outages in services from our platform; significant data breach or disruption of the information technology systems or networks and cyberattacks; risks associated with international operations; general economic and competitive factors affecting our business generally; changes in laws and regulations, including those related to privacy, online liability, consumer protection, and financial services; our dependence on senior management and other key personnel; and our ability to attract, retain and motivate qualified personnel and senior management.

Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other future filings and reports that we file with the Securities and Exchange Commission (SEC) from time to time. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the press release. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments.

November 12, 2025 08:30 ET

 | Source:

Intelligent Bio Solutions, Inc.

Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion

Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025.

The fiscal 2026 first quarter delivered record quarterly revenue of $1.11 million, driven by accelerating cartridge sales, significant customer acquisition, and strategic partnerships that position INBS for continued expansion across key international markets. The Company's consumable-focused business model demonstrated strong momentum, with cartridge sales representing nearly 58% of total revenue. Gross profit margins increased by 690 basis points year-over-year to 46.6%, due to improved operational efficiency and a greater revenue percentage from higher margin cartridge sales.

"Our first quarter results show accelerating momentum of our business model and the growing market adoption internationally of our non-invasive drug screening technology," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "We achieved record quarterly revenue of $1.11 million, representing our strongest quarter to date, with 32% growth sequentially and 28% year-over-year. This significant revenue increase, combined with expanding gross margins, validates our strategic focus on consumable cartridge sales and positions us well for sustained growth as we advance along the regulatory pathway toward planned FDA clearance and U.S. market entry."

Key Financial and Operational Highlights

Revenue of $1,111,797, up 32% sequentially from the fiscal fourth quarter 2025 and 28% year-over-year from the fiscal first quarter 2025.
Cartridge sales of $640,300 represented 57.59% of total revenue, up from 51.1% in the fiscal first quarter of 2025, demonstrating the strength of the Company's recurring revenue model.
Gross profit margins increased to 46.6% from 39.68% in the fiscal first quarter of 2025, reflecting improved operational efficiency and product mix optimization.
Added 33 new customer accounts during the quarter, bringing the Company's total number of active accounts to 492 across 24+ countries. Strategic Market Expansion and Partnerships

Secured a major contract with a London public transport operator covering 14 operational sites and over 4,400 staff, representing a significant scale deployment.
Expanded product portfolio with the addition of the SmarTest® Patch, an innovative 7-10 day continuous drug monitoring solution.
Established a global distribution agreement with SMARTOX® to bring its SmarTest Patch technology to international markets outside of the U.S. and Canada. "As our first fiscal quarter results show, the financial discipline implemented throughout fiscal 2025 is now translating into meaningful margin expansion and operational leverage," said Spiro Sakiris, CFO at Intelligent Bio Solutions. "We are seeing strong returns on strategic investments, with improved customer acquisition metrics and accelerating revenue per account. We believe that we are well positioned to capitalize on the growth opportunities ahead."

INBS's proprietary fingerprint technology addresses key pain points in drug screening, including privacy and dignity, user experience, and operational efficiency, positioning the Company to capitalize on the growing demand for non-invasive, rapid drug screening solutions. The addition of the SmarTest® Patch and SMARTOX® partnership, combined with INBS's international expansion and proven ability to secure large-scale deployments, positions the Company for continued revenue diversification and market growth throughout fiscal 2026.

About Intelligent Bio Solutions Inc.    

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

For more information, visit https://ibs.inc/ 

Forward-Looking Statements  

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.   

Company Contact   
Intelligent Bio Solutions Inc.    
[email protected]     
LinkedIn | Twitter    

Investor & Media Contact   
Valter Pinto, Managing Director    
KCSA Strategic Communications    
PH: (212) 896-1254    
[email protected]   

Intelligent Bio Solutions Inc.
Condensed Consolidated Balance Sheets
  As of September 30,  As of June 30,   2025  2025    (Unaudited)     ASSETS        Current assets        Cash and cash equivalents $1,660,105  $1,019,909 Accounts receivable, net  717,823   594,614 Inventories  628,177   635,215 Research and development tax incentive receivable  924,062   734,408 Assets held for sale  66,020   327,500 Other current assets  488,182   826,976 Total current assets  4,484,369   4,138,622 Property and equipment, net  271,745   251,325 Operating lease right-of-use assets  1,808,892   69,520 Intangibles, net  3,473,303   3,790,319 Total assets $10,038,309  $8,249,786          LIABILITIES AND SHAREHOLDERS’ EQUITY        Current liabilities        Accounts payable and accrued expenses $3,992,427  $4,534,246 Current portion of operating lease liabilities  362,801   84,659 Current employee benefit liabilities  567,059   534,990 Notes payable  139,787   197,146 Total current liabilities  5,062,074   5,351,041 Employee benefit liabilities, less current portion  100,041   84,921 Operating lease liabilities, less current portion  1,449,265   - Total liabilities  6,611,380   5,435,962 Commitments and contingencies                 Shareholders’ equity        Common stock, $0.01 par value, 100,000,000 shares authorized, 9,098,473 and 9,098,357 shares issued and outstanding, respectively, as of September 30, 2025; 7,323,377 and 7,323,261 shares issued and outstanding, respectively, as of June 30, 2025  90,985   73,230 Treasury stock, at cost, 116 shares as of September 30, 2025 and June 30, 2025  (1)  (1)Additional paid-in capital  69,325,542   65,783,916 Accumulated deficit  (65,516,071)  (62,533,065)Accumulated other comprehensive loss  (279,228)  (327,944)Total consolidated Intelligent Bio Solutions Inc. equity  3,621,227   2,996,136 Non-controlling interest  (194,298)  (182,312)Total shareholders’ equity  3,426,929   2,813,824 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $10,038,309  $8,249,786  Intelligent Bio Solutions Inc.
Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)
(Unaudited)          Three Months Ended September 30,   2025  2024 Revenue $1,111,797  $872,287 Cost of revenue (exclusive of amortization shown separately below)  (593,506)  (525,486)Gross profit  518,291   346,801          Other income        Government support income  193,267   126,128          Operating expenses        Selling, general and administrative expenses  (2,659,824)  (1,949,016)Development and regulatory approval expenses  (486,169)  (948,752)Depreciation and amortization  (303,378)  (300,422)Impairment of long-lived assets  (261,780)  - Total operating expenses  (3,711,151)  (3,198,190)Loss from operations  (2,999,593)  (2,725,261)         Other income (expense), net        Interest expense  (3,903)  (22,327)Realized foreign exchange loss  -   (51)Interest income  8,504   52,840 Total other income, net  4,601   30,462 Net loss  (2,994,992)  (2,694,799)Net loss attributable to non-controlling interest  (11,986)  (9,166)Net loss attributable to Intelligent Bio Solutions Inc. $(2,983,006) $(2,685,633)         Other comprehensive income (loss)        Foreign currency translation gain  48,716   216,355 Total other comprehensive income  48,716   216,355 Comprehensive loss  (2,946,276)  (2,478,444)Comprehensive loss attributable to non-controlling interest  (11,986)  (9,166)Comprehensive loss attributable to Intelligent Bio Solutions Inc. $(2,934,290) $(2,469,278)         Net loss per share, basic and diluted $(0.35) $(0.70)Weighted average shares outstanding, basic and diluted  8,546,934   3,811,090 

Vancouver, BC - TheNewswire - November 12, 2025 / Global Energy Metals Corporation TSXV:GEMC | OTCQB:GBLEF | FSE:5GE1 (“Global Energy Metals”, the “Company” and/or “GEMC”), a multi-jurisdictional, multi-commodity critical mineral exploration, development and project generating company focused on growth-oriented projects supporting the global transition to clean energy, announces that it has terminated the non-binding letter of intent to enter into a share purchase agreement whereby Global Energy would acquire all of the issued and outstanding common shares of Luna Energy Ltd. (the “Termination”). The Company has also cancelled the previously announced Consolidation and concurrent Financing as part of the Termination.

The Company will continue to review and evaluate potential opportunities to increase investment exposure to the new energy economy.

For Further Information:

Global Energy Metals Corporation

Email: [email protected]

www.globalenergymetals.com

Twitter: @EnergyMetals | @USBatteryMetals | @ElementMinerals

Global Energy Metals Corporation

(TSXV:GEMC | OTCQB:GBLEF | FSE:5GE1)

Global Energy Metals Corp. offers investment exposure to the growing rechargeable battery and electric vehicle market by building a diversified global portfolio of exploration and growth-stage battery mineral assets.

Global Energy Metals recognizes that the proliferation and growth of the electrified economy in the coming decades is underpinned by the availability of battery metals, including cobalt, nickel, copper, lithium and other raw materials. To be part of the solution and respond to this electrification movement, Global Energy Metals has taken a ‘consolidate, partner and invest’ approach and in doing so have assembled and are advancing a portfolio of strategically significant investments in battery metal resources.

As demonstrated with the Company’s current copper, nickel and cobalt projects in Canada, Australia, Norway and the United States, GEMC is investing-in, exploring and developing prospective, scaleable assets in established mining and processing jurisdictions in close proximity to end-use markets. Global Energy Metals is targeting projects with low logistics and processing risks, so that they can be fast tracked to enter the supply chain in this cycle.  The Company is also collaborating with industry peers to strengthen its exposure to these critical commodities and the associated technologies required for a cleaner future.

Securing exposure to these critical minerals powering the eMobility revolution is a generational investment opportunity. Global Energy Metals believes Now is the Time to be part of this electrification movement.    

Cautionary Statement on Forward-Looking Information:  

Certain information in this release may constitute forward-looking statements under applicable securities laws and necessarily involve risks associated with regulatory approvals and timelines. Although Global Energy Metals believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Except as required by law, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.  

GEMC’s operations could be significantly adversely affected by the effects of a widespread global outbreak of a contagious disease, including the recent outbreak of illness caused by COVID-19. It is not possible to accurately predict the impact COVID-19 will have on operations and the ability of others to meet their obligations, including uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, and the length of travel and quarantine restrictions imposed by governments of affected countries. In addition, a significant outbreak of contagious diseases in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could further affect operations and the ability to finance its operations.

For more information on Global Energy and the risks and challenges of their businesses, investors should review the filings that are available at www.sedar.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

We seek safe harbour.

WESTMINSTER, MA / ACCESS Newswire / November 12, 2025 / TechPrecision Corporation (NASDAQ:TPCS) ("TechPrecision" or "the Company"), a custom manufacturer of precision, large-scale fabrication components and precision, large-scale machined metal structural components, today announced it plans to release financial results for its 2026 fiscal second quarter on Thursday, November 13, 2025 after market close.

The Company will hold a conference call at 4:30 p.m. Eastern (U.S.) time on Thursday, November 13, 2025. To participate in the live conference call, please dial 1-877-545-0523 five to 10 minutes prior to the scheduled conference call time. International callers should dial 1-973-528-0016. When prompted, reference TechPrecision and enter code 305080.

A replay will be available until November 27, 2025. To access the replay, dial 1-877-481-4010 or 1-919-882-2331. When prompted, enter Conference Passcode 53138.

The call will also be available over the Internet and accessible at: https://www.webcaster5.com/Webcast/Page/2198/53138.

About TechPrecision Corporation

TechPrecision Corporation, through its wholly owned subsidiaries, Ranor, Inc. and Stadco, The manufacturing operations of our Ranor subsidiary are situated on approximately 65 acres in North Central Massachusetts. Leveraging our 145,000 square foot facilities, Ranor provides a full range of custom solutions to transform material into precision finished welded components and precision finished machined components up to 100 tons: manufacturing engineering, materials management and traceability, high-precision heavy fabrication (in-house fabrication operations include cutting, press and roll forming, welding, heat treating, assembly, blasting and painting), heavy high-precision machining (in-house machining operations include CNC programming, finishing, and assembly), QC inspection including portable CMM, NonDestructive Testing, and final packaging.

All manufacturing at Ranor is performed in accordance with customer requirements. Ranor is an ISO 9001:2015 certificate holder. Ranor is a US defense-centric company with over 95% of its revenue in the defense sector. Ranor is registered and compliant with ITAR.

The manufacturing operations of our Stadco subsidiary are situated in an industrial self-contained multi-building complex comprised of approximately 183,000 square feet under roof in Los Angeles, California. Stadco manufactures large mission-critical components on several high-profile military aircraft, military helicopter, and military space programs. Stadco has been a critical supplier to a blue-chip customer base that includes some of the largest OEMs and prime contractors in the defense and aerospace industries. Stadco also manufactures tooling, molds, fixtures, jigs and dies used in the production of defense-centric aircraft components.

Our Stadco subsidiary, similar to Ranor, provides a full range of custom solutions: manufacturing engineering, materials management and traceability, high-precision fabrication (in-house fabrication operations include waterjet cutting, press forming, welding, and assembly) and high-precision machining (in-house machining operations include CNC programming, finishing, and assembly), QC inspection including both fixed and portable CMM NonDestructive Testing, and final packaging. In addition, Stadco features a large electron beam welding cell, and two NonDestructive Testing work cells, a unique mission-critical technology set.

All manufacturing at Stadco is performed in accordance with customer requirements. Stadco is an AS 9100 D and ISO 9001:2015 certificate holder and a NADCAP NonDestructive Testing certificate holder. Stadco is a US defense-centric company with over 60% of its revenue in the defense sector. Stadco is registered and compliant with ITAR.

To learn more about the Company, please visit the corporate website at http://www.techprecision.com. Information on the Company's website or any other website does not constitute a part of this press release.

Company Contact:

Investor Relations Contact:

Alexander Shen

Hayden IR

Chief Executive Officer

Brett Maas

TechPrecision Corporation

Phone: 646-536-7331

Phone: (978) 874-0591

Email: [email protected]

Email: [email protected]

Website: www.haydenir.com

Website: www.techprecision.com

SOURCE: TechPrecision Corporation

November 12, 2025 8:30 AM EST | Source: Eco Wave Power Global AB (publ)
Q3 2025 marks significant progress with the launch of Eco Wave Power's first U.S. project, strategic advancements across Europe, Asia, and Africa, recognition by TIME as one of the Best Inventions of 2025, and a solid financial foundation to support ongoing global growth and commercialization of wave energy technology

Stockholm, Sweden--(Newsfile Corp. - November 12, 2025) - Eco Wave Power Global AB (publ) (NASDAQ: WAVE) ("Eco Wave Power" or the "Company"), a global leader in onshore wave energy technology, today announced its financial results for the nine months ended September 30, 2025, along with an update on its rapidly expanding international project portfolio.

Management Commentary

Q3 2025 has been a period of significant operational progress and international recognition for Eco Wave Power. Across all active project regions, the Company has continued to advance its mission of delivering reliable, clean, and commercially viable wave energy solutions, while maintaining a solid financial foundation. Operating expenses increased modestly by $65 thousand compared to Q2 2025, reflecting targeted investments in project execution and growth initiatives. As of September 30, 2025, the Company held $6.85 million in cash and short-term deposits, supporting ongoing development and global expansion.

United States: Los Angeles Project Launch and Recognition as TIME's Best Inventions and "Future of Everything" on NBC News.

In August 2025, Eco Wave Power announced that its U.S. pilot project at the Port of Los Angeles has successfully completed operational testing and achieved a historic milestone: the lowering of its innovative floaters into the water for the very first time. This major moment was broadcasted live and exclusively by Good Morning America, marking unprecedented national visibility for the advancement of wave energy technology.

On September 9th, 2025, Eco Wave Power hit a historic milestone and launched the first ever U.S. Wave Energy Project at Port of Los Angeles, developed in collaboration with AltaSea and Shell Marine Renewable Energy (MRE).

This historic project marks the first onshore wave energy installation in the U.S., showcasing Eco Wave Power's patented, award-winning technology and setting the stage for large-scale wave energy deployment along America's coastlines and worldwide. It also showcases our commitment to innovation, ESG leadership, and local economic engagement, including working with woman- and family-owned businesses.

The launch comes at a pivotal time for California, aligning with the state's bold climate policies and Senate Bill 605, which calls for the creation of a comprehensive wave energy roadmap. Federal support is also growing, led by Congresswoman Nanette Díaz Barragán, who recently introduced the Marine Energy Technologies Acceleration Act, a $1 billion initiative to scale marine energy across the nation.

On October 2025, U.S. Congresswoman Nanette Barragán (CA-44) visited the Company's onshore wave energy pilot station at AltaSea in the Port of Los Angeles and called for $1B Federal Investment in Wave Energy. The visit underscores the enormous potential for wave energy to become a major renewable energy source for U.S. coastal communities.

During the same month, Eco Wave Power's pilot was named to TIME's Best Inventions of 2025 list, recognizing it as one of 300 innovations worldwide "changing the way we live, work, and think." The selection followed TIME's rigorous evaluation of originality, efficacy, ambition, and impact, with particular focus on solutions addressing climate change and sustainability. This recognition underscores Eco Wave Power's role in advancing wave energy as a meaningful new source of renewable power and was also featured in the "Feature of Everything" News Segment by NBC.

Taiwan
We commenced our Taiwan entry through an agreement with I-Ke International Ocean Energy Co., a subsidiary of Lian Tat Company. The project includes:

Local manufacturing of floaters under our patented design.Supply of a turnkey 100KW conversion unit.I-Ke's responsibility for permitting and onshore production.In August 2025 I-KE was awarded the official land use tender from the Suao Port Company for the installation of a wave energy pilot station in Taiwan. This achievement marks the first time in Taiwan's history that a commercial port area has been opened for wave power testing, highlighting the nation's commitment to innovation and clean energy.

This tender award is a first-of-its-kind event in Taiwan, setting an important precedent for the country's renewable energy sector. It directly supports Taiwan's national renewable energy transition strategy and positions Suao Port as a demonstration hub for low-carbon, smart, and innovative green energy. Facing the Pacific Ocean, the site offers stable, representative wave conditions with strong potential for commercial-scale wave power generation. The pilot project at Zone C is intended to serve as the foundation for a phased development roadmap, expanding to 20 MW in the medium term and potentially up to 400 MW of capacity across Taiwan's coastline.

India
Earlier this year, we signed an MoU with Bharat Petroleum Corporation Limited (BPCL), a Fortune 500 government-owned company, to explore wave energy deployment at the Mumbai Oil Terminal. BPCL will manage regulatory clearances, while we provide technology and optimization expertise. The collaboration — endorsed by India's Minister of Petroleum and Natural Gas — begins with a site assessment and is expected to lead to a pilot project in the world's ~40,000 MW ocean energy market.

During this quarter Eco Wave Power has entered an agreement with RL Solutions, a local representative for the Company, meant to facilitate the purchase order from Bharat Petroleum to Eco Wave Power.

Europe: First Megawatt-Scale Project in Portugal
We advanced preparations for Portugal's first MW-scale wave energy power plant under our 20MW concession with Administração dos Portos do Douro, Leixões e Viana do Castelo, S.A. (APDL).

The Company also achieved the following tasks:

Development of an advanced calculation tool together with Metocean to improve the accuracy of force analysis and station performance.Finalizing the design of drilling structures that will enable continuous work regardless of tide levels.Submission of the safety plan for the drilling and installation of the floaters.In conclusion, during this quarter, we have conducted an in-depth analysis of the wave forces, finalized the execution plan, and submitted to APDL a final revised execution plan in October 2025. As soon as the green light is provided by APDL, Eco Wave Power will proceed to the next step and intends to enter into subcontractor agreements with key subcontractors such as Siemens for the electric part of the project and others.

The 1MW plant — planned for grid connection in 2026 — is designed to serve as a gateway for commercialization in Portugal, aligning with the country's renewable energy strategy.

Israel: EWP-EDF One as an R&D Powerhouse
Following its inauguration in December 2024, the EWP-EDF One project at Jaffa Port became Israel's first grid-connected wave energy system, operating under a Power Purchase Agreement with the Israeli Electric Corporation and recognized by the Ministry of Energy as "Pioneering Technology."

Building on the operational insights gained from the EWP-EDF One project at Jaffa Port, Q3 focused on preparing the station for advanced testing under diverse sea conditions. Eco Wave Power initiated a dedicated project to calibrate the hydraulic system for varying wave states, with the objective of optimizing system responsiveness, efficiency, and reliability across a wider operational range.

This calibration program will continue throughout the winter months, when higher and more energetic sea conditions are expected. The collected data will be used to fine-tune system parameters, validate predictive models, and support ongoing R&D aimed at improving power conversion performance and operational resilience.

By leveraging real-sea conditions at Jaffa Port, Eco Wave Power continues to strengthen its position as a global R&D hub for onshore wave energy. While Jaffa Port experiences waves above 0.7 m about 30% of the time—making it a valuable R&D site rather than a 24/7 production facility—locations such as Portugal can offer around 90% availability. This enables wave energy to achieve substantially higher energy output per site footprint compared to other renewables, while utilizing existing port infrastructure and minimal land.

Eco Wave Power will continue investing in R&D to lower equipment costs, advance toward competitive levelized costs of energy (LCOE), and unlock larger-scale commercial projects that can enhance value for partners and shareholders.

Africa: Progress with Feasibility Study in South Africa
In October 2025, we submitted a detailed MetOcean Report for the wave potential and wave forces at the Port of Ngqura, in line with the agreement with Africa Great Future Development Ltd (AGFDL). South Africa's 2,800+ km coastline and need for energy diversification make it a compelling long-term market. The port's breakwater infrastructure and deep-water access are ideal for our system's deployment.

Financial Overview
In Q3 2025, Eco Wave Power continued to strategically invest in growth while maintaining a strong financial position. Operating expenses increased 8% quarter-over-quarter to $888 thousand, reflecting a deliberate increase in Sales & Marketing spend to support the successful launch of our U.S. project. These investments were partially offset by lower R&D expenses (-12%) and reduced G&A costs (-5%), demonstrating disciplined cost management across other areas of the business.

Other income nearly doubled, while financial expenses decreased by 81% due to lower foreign exchange losses. As a result, net loss declined by 28% quarter-over-quarter to $996 thousand, underscoring improved operational efficiency and financial discipline.

The Company closed the quarter with a robust cash position of $6.85 million in cash and short-term deposits, providing a solid foundation to execute near-term project milestones, accelerate global expansion, and capitalize on emerging opportunities in the rapidly growing renewable energy market.

CEO commentary:

This quarter marks a historic period for Eco Wave Power, as we achieve major milestones that reinforce our position as a global leader in wave energy technology.

The successful launch of our first U.S. project at the Port of Los Angeles represents not only a technical achievement but also a moment of unprecedented visibility for wave energy, highlighted by national coverage on Good Morning America and recognition by TIME as one of the Best Inventions of 2025.

Our U.S. pilot project demonstrates the reliability and scalability of our patented floaters and positions Eco Wave Power at the forefront of a rapidly emerging wave energy market in the United States.

The engagement from local partners, including AltaSea, Shell Marine Renewable Energy, and small woman- and family-owned businesses, underscores our commitment to innovation, ESG principles, and community impact.

Beyond the United States, we have made meaningful progress across multiple continents. In Taiwan, our partnership with I-Ke International Ocean Energy has resulted in the first-ever commercial port area tender for wave energy testing, laying the foundation for medium- and long-term expansion.

In India, our collaboration with Bharat Petroleum establishes a foothold in one of the world's largest untapped ocean energy markets, while in Europe, we continue preparations for Portugal's first megawatt-scale plant, aligning with the country's renewable energy roadmap.

Our operations in Israel continue to strengthen our R&D capabilities, with the EWP-EDF One project at Jaffa Port enabling advanced testing and calibration to improve efficiency, reliability, and predictive modelling.

Similarly, in Africa, we are advancing feasibility studies to explore wave energy opportunities at the Port of Ngqura, positioning us to support emerging energy markets with scalable, clean solutions.

We are proud that our progress is supported by a solid financial foundation, with $6.85 million in cash and short-term deposits to fuel ongoing growth and execution. While operating expenses increased modestly by $65 thousand compared to Q2, these investments directly support our strategic expansion and project execution globally.

Our disciplined financial management this quarter, combined with targeted investments in Sales & Marketing for the U.S. project launch, enabled us to reduce net loss by 28% quarter-over-quarter to $996 thousand. Operating expenses reflected strategic increases in Sales & Marketing, partially offset by reductions in R&D (-12%) and G&A (-5%), demonstrating our focus on both growth and efficiency. Other income nearly doubled, and financial expenses decreased by 81% due to lower foreign exchange losses, further strengthening our financial position.

Looking ahead, global electricity demand is accelerating at an unprecedented pace, fueled by the rapid growth of energy-intensive sectors such as artificial intelligence, data centers, and advanced manufacturing. Eco Wave Power is uniquely positioned to meet this challenge, delivering scalable, reliable, and renewable wave energy solutions that can power the industries of tomorrow while supporting the global energy transition. Our technology is not only an environmentally responsible solution, it is a strategic answer to the world's urgent need for clean, abundant electricity.

Inna Braverman, CEO

Nine Months Ended September 30, 2025 Financial Overview

For the nine months ended September 30, 2025, operating expenses increased to $2.48 million compared to $1,966 thousand for the nine months ended September 30, 2024, primarily due to investments in the U.S., in Portugal, and in Asia projects.

Research and development expenses rose by $157 thousand, to $591 thousand for the nine months ended September 30, 2025, compared to $434 thousand for the nine months ended September 30, 2024, mainly to support engineering efforts and project development.

Sales and Marketing costs increased by $82 thousand to $293 thousand for the nine months ended September 30, 2025, compared to $211 thousand for the nine months ended September 30, 2024, reflecting the U.S. pilot project launch.

General & Administrative expenses increased by $295 thousand to $1,611 thousand for the nine months ended September 30, 2025, compared to $1,316 thousand for the nine months ended September 30, 2024, driven by staffing, professional fees, and travels for international expansion.

Other income more than doubled to $78 thousand for the nine months ended September 30, 2025 compared to $36 thousand for the nine months ended September 30, 2024, reflecting gains from demonstrating our technology in Asia and a gain on extinguishment of financial liability.

Net financial loss was $412 thousand for the nine months ended September 30, 2025, compared to $394 thousand net financial income for the nine months ended September 30, 2024, reflecting foreign exchange loss resulting from the appreciation of the SEK and the NIIS against the U.S. dollar.

Net loss increased to $2,888 thousand for the nine months ended September 30, 2025, compared to $1,572 thousand for the nine months ended September 30, 2024, reflecting higher operating expenses and foreign exchange impacts. The Company maintained a strong cash position of $6.85 million, supporting ongoing execution and global expansion plans.

Conference Call and Webcast Information

The Chief Executive Officer of Eco Wave Power, Inna Braverman and the Company's Chief Financial Officer, Aharon Yehuda, will host a conference call to discuss the financial results and outlook on Thursday, November 13, 2025, at 9:00 AM Eastern time.

The dial-in numbers for the conference call are 877-545-0523 (toll-free) or +973-528-0016 (international).
If requested, please provide participant access code: 299747.The event will be webcast live, available at: https://www.webcaster5.com/Webcast/Page/2922/53236A replay will be available by telephone approximately four hours after the call's completion until Thursday, November 27, 2025. You may access the replay by dialing 877-481-4010 from the U.S. or 919-882-2331 for international callers, using the Replay ID 53236. The archived webcast will also be available on the investor relations section of the Company's website.

About Eco Wave Power Global AB (publ)

Eco Wave Power Global (NASDAQ: WAVE) is a pioneering onshore wave energy company that transforms the power of ocean and sea waves into clean, reliable, and cost-efficient electricity through its patented, intelligent technology.

With a mission to accelerate the global transition to renewable energy, Eco Wave Power developed and operates Israel's first grid-connected wave energy power station, recognized as a "Pioneering Technology" by the Israeli Ministry of Energy and co-funded by EDF Renewables IL. In the United States, the company recently launched the first-ever onshore wave energy pilot station at the Port of Los Angeles, in collaboration with Shell Marine Renewable Energy (Shell MRE).

Eco Wave Power is expanding rapidly worldwide, with upcoming projects in Portugal, Taiwan, and India, representing a robust project pipeline of 404.7 MW under development. The company has received international recognition and support from organizations including the European Union Regional Development Fund, Innovate UK, and the EU Horizon 2020 program, and was honored with the United Nations Global Climate Action Award.

Eco Wave Power's American Depositary Shares (ADSs) are traded on the Nasdaq Capital Market under the ticker symbol "WAVE."

For more information, please visit www.ecowavepower.com.

Note: Information available on or through the websites mentioned herein does not form part of this press release.

For press inquiries, please contact: [email protected]

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward-looking statements in this press release when it discusses its expectation that there is enormous potential for wave energy to become a major renewable energy source for U.S. coastal communities, the expectation that the Company intends to enter into subcontractor agreements with key subcontractors such as Siemens for the first MW-scale wave energy project in Portugal, that the MoU the Company signed with Bharat Petroleum is expected to lead to a pilot project in the world's ~40,000 MW ocean energy market, the Suao Port in Taiwan offers stable, representative wave conditions with strong potential for commercial-scale wave power generation, that the Suao Port pilot project at Zone C is intended to serve as the foundation for a phased development roadmap, expanding to 20 MW in the medium term and potentially up to 400 MW of capacity across Taiwan's coastline, and that the Company will continue investing in R&D to lower equipment costs, advance toward competitive levelized costs of energy (LCOE), and unlock larger-scale commercial projects that can enhance value for partners and shareholders. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will", or variations of such words, and similar references to future periods. These forward-looking statements and their implications are neither historical facts nor assurances of future performance and are based on the current expectations of the management of Eco Wave Power and are subject to a number of factors, uncertainties and changes in circumstances that are difficult to predict and may be outside of Eco Wave Power's control that could cause actual results to differ materially from those described in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Except as otherwise required by law, Eco Wave Power undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting Eco Wave Power is contained under the heading "Risk Factors" in Eco Wave Power's Annual Report on Form 20-F for the fiscal year ended December 31, 2024 filed with the SEC on March 3, 2025, which is available on the on the SEC's website, www.sec.gov, and other documents filed or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. References and links to websites have been provided as a convenience and the information contained on such websites is not incorporated by reference into this press release.

Eco Wave Power Global AB (publ)
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited)

 September 30, 2025 December 31, 2024
 In USD thousands      Assets
 
CURRENT ASSETS:
 
Cash and cash equivalents5,302 7,845Short term bank deposits1,302 1,254Restricted short-term bank deposits248 220Trade receivables- 33Other receivables and prepaid expenses131 93TOTAL CURRENT ASSETS6,983 9,445

 
NON-CURRENT ASSETS:
 
Property and equipment, net965 561Right-of-use assets, net171 195Investments in a joint venture accounted for using
the equity method513 481TOTAL NON-CURRENT ASSETS1,649 1,237TOTAL ASSETS8,633 10,682    Liabilities and equity
 
CURRENT LIABILITIES:
 
Loans from related party 1,033 1,011Current maturities of long-term loan135 91Accounts payable and accruals:
 
Trade63 70Other1,110 969Short term lease liabilities149 98TOTAL CURRENT LIABILITIES2,490 2,239

 
NON-CURRENT LIABILITIES:
 
Long-term loan 27 47Lease liabilities, net of current maturities20 96TOTAL NON-CURRENT LIABILITIES47 143

 
TOTAL LIABILITIES2,537 2,382

 
EQUITY:
 
Common shares102 102Share premium25,872 25,845Treasury shares(77) (50)Foreign currency translation reserve(1,680) (2,368)Accumulated deficit(17,931) (15,071)Capital and reserves attributable to parent company
shareholders6,286 8,458Non-Controlling interest(190) (158)TOTAL EQUITY6,096 8,300TOTAL LIABILITIES AND EQUITY8,633 10,682Eco Wave Power Global AB (publ)
CONDENSED CONSOLIDATED STATEMENTS OF LOSS (Unaudited)

Three months ended Nine months ended
September 30 September 30
2025 2024 2025 2024
In USD ThousandsOPERATING EXPENSES
 
 
 
Research and development expenses(192) (114) (591) (434) Sales and marketing expenses(170) (74) (293) (211) General and administrative expenses(522) (422) (1,611) (1316) Other income16 4 78 36 Share of net loss of a joint venture
 
 
 
accounted for using the equity method(20) (11) (59) (41)TOTAL OPERATING EXPENSES(888) (617) (2,476) (1,966)

 
 
 
OPERATING LOSS(888) (617) (2,476) (1,966)

 
 
 
Financial expenses(194) (110) (638) (137)Financial income86 173 226 531FINANCIAL (LOSS) INCOME - NET (108) 63 (412) 394

 
 
 
NET LOSS(996) (554) (2,888) (1,572)

 
 
 
ATTRIBUTABLE TO:
 
 
 
The Parent Company shareholders(984) (549) (2,861) (1,550)Non-controlling interests(12) (5) (27) (22)
(996) (554) (2,888) (1,572)

 
 
 

In USDLOSS PER COMMON SHARE - BASIC AND (0.02) (0.01) (0.06) (0.04)DILUTED

 
 
 
WEIGHTED AVERAGE NUMBER OF  
 
 
 
COMMON SHARES USED INCALCULATION OF LOSS PER COMMON SHARE46,710,187 44,375,272 46,724,987 44,394,114

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274141

Next-generation metabolomics and AI technology supports the 2026 - 2035 Pan-Canadian Lung Cancer Action Plan's call to expand equitable access to life-saving early diagnosis
November 12, 2025 8:30 AM EST | Source: BioMark Diagnostics, Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to support the Canadian Cancer Society's national plan to reduce lung cancer mortality in Canada by 30% over the next decade.

The early detection activities and goals outlined in the 2026-2035 Pan-Canadian Lung Cancer Action Plan are highly aligned with BioMark's corporate mission of leading the world in early-stage cancer detection using metabolomics and artificial intelligence. This coordinated national effort recognizes that early detection is fundamental to saving lives and underscores the urgent need to expand access to innovative screening solutions across all Canadian communities.

"At BioMark, we believe that providing equitable, evidence-based access to early lung cancer detection will transform patient outcomes across Canada," said Rashid Bux, CEO and President, BioMark Diagnostics. "Our clinical results demonstrate the power of AI-enabled biomarker testing in identifying more early-stage cancers, even in non-smokers, directly supporting the Action Plan's commitment to saving lives nationwide. Our technology complements low-dose CT screening, addresses barriers in underserved and remote regions, and helps ensure that no Canadian is left behind in the fight against lung cancer."

The Action Plan also notes the need for innovative diagnostic tools and methods, like blood-based biomarker testing, to improve diagnostic accuracy and increase the likelihood of early-stage diagnosis. BioMark looks forward to collaborating with national partners, provincial healthcare providers, and community organizations to build capacity and make early lung cancer detection accessible, equitable, and effective across Canada. Healthcare providers and organizations interested in partnering to expand access to innovative early detection solutions are encouraged to contact BioMark.

About the Pan-Canadian Lung Cancer Action Plan
The 2026-2035 Pan-Canadian Lung Cancer Action Plan is a coordinated national strategy from the Canadian Cancer Society to reduce lung cancer mortality through improved prevention, early detection, treatment, and support. More information is available at: https://cancer.ca/en/about-us/lung-cancer-action-plan.

About BioMark Diagnostics Inc.

BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.

Further information about BioMark is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com/.

For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: [email protected]

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved, or disapproved of the content of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274109